Bone density, microarchitecture and tissue quality following long-term treatment with tenofovir/emtricitabine or abacavir/lamivudine.

HIV infection has been associated with reduced bone mineral density (BMD). Antiretroviral therapy has a deleterious effect on BMD, but its effect on bone fragility is not clear. Long-term treatment with TDF-FTC leads to impaired bone health, not only in terms of BMD, but also in terms of bone quality, another determinant of overall bone strength. To complement BMD-based predictions, these other techniques may also be used to identify patients with excess fracture risk.

J Acquir Immune Defic Syndr. 2017 Apr 7.

Más información

Güerri-Fernández R, Molina-Morant D, Villar-García J, Herrera S, González-Mena A, Guelar A, Trenchs-Rodríguez M, Díez-Pérez A, Knobel H.

Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen
Gebro